Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald B Appel

Showing results (1-10 of 140) with videos related to

Pageof 14
Sort By:
Mayo Clinic Proceedings|August 6, 2018
C3 Glomerulopathy: A New Disease Comes of AgeGerald B Appel
Journal of the American Society of Nephrology : JASN|July 17, 2012
Rituximab in membranous nephropathy: is it a first-line treatment?Gerald B Appel
Clinical Journal of the American Society of Nephrology : CJASN|August 21, 2007
To treat or not to treat IgA nephropathy? That is the question!Gerald B Appel
Contributions to Nephrology|May 22, 2013
Membranoprolferative glomerulonephritis - mechanisms and treatmentGerald B Appel
Cleveland Clinic Journal of Medicine|February 16, 2017
Thrombotic microangiopathies: Similar presentations, different therapiesGerald B Appel
Cleveland Clinic Journal of Medicine|February 4, 2012
New and future therapies for lupus nephritisGerald B Appel
Nature Reviews. Nephrology|November 17, 2015
Therapy: New data do not support use of abatacept in diabetic nephropathyGerald B Appel
Cleveland Clinic Journal of Medicine|February 16, 2006
Improved outcomes in nephrotic syndromeGerald B Appel
Clinical Journal of the American Society of Nephrology : CJASN|August 26, 2020
Mycophenolate Mofetil Treatment of C3 GlomerulopathyYonatan Peleg, Gerald B Appel
Current Opinion in Nephrology and Hypertension|January 19, 2013
Update on the treatment of lupus nephritisJonathan Hogan, Gerald B Appel
Pageof 14

Showing results (1-10 of 140) with videos related to

Sort By:
Pageof 14
Mayo Clinic Proceedings|August 6, 2018
C3 Glomerulopathy: A New Disease Comes of AgeGerald B Appel
Journal of the American Society of Nephrology : JASN|July 17, 2012
Rituximab in membranous nephropathy: is it a first-line treatment?Gerald B Appel
Clinical Journal of the American Society of Nephrology : CJASN|August 21, 2007
To treat or not to treat IgA nephropathy? That is the question!Gerald B Appel
Contributions to Nephrology|May 22, 2013
Membranoprolferative glomerulonephritis - mechanisms and treatmentGerald B Appel
Cleveland Clinic Journal of Medicine|February 16, 2017
Thrombotic microangiopathies: Similar presentations, different therapiesGerald B Appel
Cleveland Clinic Journal of Medicine|February 4, 2012
New and future therapies for lupus nephritisGerald B Appel
Nature Reviews. Nephrology|November 17, 2015
Therapy: New data do not support use of abatacept in diabetic nephropathyGerald B Appel
Cleveland Clinic Journal of Medicine|February 16, 2006
Improved outcomes in nephrotic syndromeGerald B Appel
Clinical Journal of the American Society of Nephrology : CJASN|August 26, 2020
Mycophenolate Mofetil Treatment of C3 GlomerulopathyYonatan Peleg, Gerald B Appel
Current Opinion in Nephrology and Hypertension|January 19, 2013
Update on the treatment of lupus nephritisJonathan Hogan, Gerald B Appel
Pageof 14